PURPOSE: The aim of our study was to analyze changes in the consumption of MRSA-active antibiotics and in the burden of methicillin-resistant S. aureus (MRSA) over a period of 9 years in a network of German intensive care units (ICU). METHODS: Data from 55 ICUs in Germany were analyzed from 2001 through 2009. The term "old MRSA-active antibiotics" included vancomycin, teicoplanin and fosfomycin, whereas the term "new MRSA-active antibiotics" included quinupristin/dalfopristin, linezolid and daptomycin. The burden of MRSA was defined as MRSA per 1,000 patient-days. RESULTS: A total of 1,584,995 patient-days and 32,450 S. aureus isolates were analyzed. The burden of MRSA was 4.4, and the pooled mean MRSA resistance proportion was 21.8%. Both parameters did not change significantly over time. In contrast, MRSA-active antibiotics more than doubled from 44 defined daily doses per 1,000 patient-days in 2001 to 92 in 2009. This was due to the significant increase of new MRSA-active antibiotics (from 1 to 40), whereas old MRSA antibiotics stayed stable (43 in 2001 and 52 in 2009). CONCLUSION: New MRSA-active antibiotics did not replace old ones, but were added on top. The use of new MRSA-active antibiotics-mainly linezolid-steadily increased over a period of 9 years, although the burden of MRSA stayed stable, as did the proportion of MRSA (%).
PURPOSE: The aim of our study was to analyze changes in the consumption of MRSA-active antibiotics and in the burden of methicillin-resistant S. aureus (MRSA) over a period of 9 years in a network of German intensive care units (ICU). METHODS: Data from 55 ICUs in Germany were analyzed from 2001 through 2009. The term "old MRSA-active antibiotics" included vancomycin, teicoplanin and fosfomycin, whereas the term "new MRSA-active antibiotics" included quinupristin/dalfopristin, linezolid and daptomycin. The burden of MRSA was defined as MRSA per 1,000 patient-days. RESULTS: A total of 1,584,995 patient-days and 32,450 S. aureus isolates were analyzed. The burden of MRSA was 4.4, and the pooled mean MRSA resistance proportion was 21.8%. Both parameters did not change significantly over time. In contrast, MRSA-active antibiotics more than doubled from 44 defined daily doses per 1,000 patient-days in 2001 to 92 in 2009. This was due to the significant increase of new MRSA-active antibiotics (from 1 to 40), whereas old MRSA antibiotics stayed stable (43 in 2001 and 52 in 2009). CONCLUSION: New MRSA-active antibiotics did not replace old ones, but were added on top. The use of new MRSA-active antibiotics-mainly linezolid-steadily increased over a period of 9 years, although the burden of MRSA stayed stable, as did the proportion of MRSA (%).
Authors: John H Powers; David B Ross; Erica Brittain; Renata Albrecht; Mark J Goldberger Journal: Clin Infect Dis Date: 2002-03-15 Impact factor: 9.079
Authors: Michael J Rybak; Ben M Lomaestro; John C Rotschafer; Robert C Moellering; Willam A Craig; Marianne Billeter; Joseph R Dalovisio; Donald P Levine Journal: Clin Infect Dis Date: 2009-08-01 Impact factor: 9.079
Authors: Geoffrey K Spurling; Peter R Mansfield; Brett D Montgomery; Joel Lexchin; Jenny Doust; Noordin Othman; Agnes I Vitry Journal: PLoS Med Date: 2010-10-19 Impact factor: 11.069
Authors: Frieder Schaumburg; Robin Köck; Alexander Mellmann; Laura Richter; Felicitas Hasenberg; André Kriegeskorte; Alexander W Friedrich; Sören Gatermann; Georg Peters; Christof von Eiff; Karsten Becker Journal: J Clin Microbiol Date: 2012-07-18 Impact factor: 5.948
Authors: B Schweickert; I Noll; M Feig; H Claus; G Krause; E Velasco; T Eckmanns Journal: Eur J Clin Microbiol Infect Dis Date: 2011-12-31 Impact factor: 3.267
Authors: Gennaro De Pascale; Serena Fortuna; Mario Tumbarello; Salvatore Lucio Cutuli; MariaSole Vallecoccia; Teresa Spanu; Giuseppe Bello; Luca Montini; Mariano Alberto Pennisi; Pierluigi Navarra; Massimo Antonelli Journal: Intensive Care Med Date: 2014-11-21 Impact factor: 17.440
Authors: Massimo Antonelli; Marc Bonten; Jean Chastre; Giuseppe Citerio; Giorgio Conti; J Randall Curtis; Daniel De Backer; Goran Hedenstierna; Michael Joannidis; Duncan Macrae; Jordi Mancebo; Salvatore M Maggiore; Alexandre Mebazaa; Jean-Charles Preiser; Patricia Rocco; Jean-François Timsit; Jan Wernerman; Haibo Zhang Journal: Intensive Care Med Date: 2012-01-20 Impact factor: 17.440